Han Sanghoon, Bui Ngoc Thuy, Ho Manh Tin, Kim Young Mee, Cho Moonjae, Shin Dong Bok
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
Department of Biochemistry, Jeju National University School of Medicine, Jeju, Korea.
Cancer Res Treat. 2016 Jul;48(3):1141-53. doi: 10.4143/crt.2015.209. Epub 2015 Dec 15.
One of the features in cancer development is the migration of cancer cells to form metastatic lesions. CYR61 protein promotes migration and the epithelial-mesenchymal transition in several cancer cell types. Evidence suggests that CYR61 and dexamethasone are relevant to colorectal cancer. However, relationships between them and colorectal cancer are still unclear. Understanding the molecular mechanism of colorectal cancer progression related with CYR61 and dexamethasone, which is widely used for combination chemotherapy, is necessary for improved therapy.
We used colorectal cancer cells, HCT116, co-treated with transforming growth factor β1 (TGF-β1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay. Alternatively, both migratory pathways, expression of AKT and ERK, and the target factor CYR61 was also tested by co-treatment with TGF-β1 and dexamethasone.
We report that dexamethasone significantly inhibited TGF-β1-induced cell migration, without affecting cell proliferation. Importantly, we observed that TGF-β1 promoted the epithelial-mesenchymal transition process and that dexamethasone co-treatment abolished this effect. ERK and AKT signaling pathways were found to mediate TGF-β1-induced migration, which was inhibited by dexamethasone. In addition, TGF-β1 treatment induced CYR61 expression whereas dexamethasone reduced it. These observations were compatible with the modulation of migration observed following treatment of HCT116 cells with human recombinant CYR61 and anti-CYR61 antibody. Our results also indicated that TGF-β1 enhanced collagen I and reduced matrix metalloproteinase 1 expression, which was reversed by dexamethasone treatment.
These findings suggested that dexamethasone inhibits AKT and ERK phosphorylation, leading to decreased CYR61 expression, which in turn blocks TGF-β1-induced migration.
癌细胞迁移形成转移灶是癌症发展的特征之一。CYR61蛋白在几种癌细胞类型中促进细胞迁移和上皮-间质转化。有证据表明CYR61和地塞米松与结直肠癌有关。然而,它们与结直肠癌之间的关系仍不清楚。了解与广泛用于联合化疗的CYR61和地塞米松相关的结直肠癌进展分子机制,对于改善治疗是必要的。
我们使用结直肠癌细胞HCT116,与转化生长因子β1(TGF-β1)和地塞米松共同处理,通过迁移试验检测地塞米松的抑制迁移作用。另外,还通过与TGF-β1和地塞米松共同处理来测试两条迁移途径、AKT和ERK的表达以及靶因子CYR61。
我们报告地塞米松显著抑制TGF-β1诱导的细胞迁移,而不影响细胞增殖。重要的是,我们观察到TGF-β1促进上皮-间质转化过程,而地塞米松共同处理消除了这种作用。发现ERK和AKT信号通路介导TGF-β1诱导的迁移,而地塞米松抑制了这种迁移。此外,TGF-β1处理诱导CYR61表达,而地塞米松降低其表达。这些观察结果与用人重组CYR61和抗CYR61抗体处理HCT116细胞后观察到的迁移调节一致。我们的结果还表明,TGF-β1增强I型胶原并降低基质金属蛋白酶1表达,而地塞米松处理可逆转这种情况。
这些发现表明,地塞米松抑制AKT和ERK磷酸化,导致CYR61表达降低,进而阻断TGF-β1诱导的迁移。